London Co. of Virginia Grows Stake in Enovis Co. (NYSE:ENOV)

London Co. of Virginia increased its stake in Enovis Co. (NYSE:ENOV - Free Report) by 8.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 468,799 shares of the company's stock after buying an additional 36,670 shares during the period. London Co. of Virginia owned 0.82% of Enovis worth $20,571,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. Aster Capital Management DIFC Ltd purchased a new position in shares of Enovis during the 4th quarter worth $29,000. Quadrant Capital Group LLC boosted its stake in shares of Enovis by 53.0% during the 4th quarter. Quadrant Capital Group LLC now owns 690 shares of the company's stock worth $30,000 after acquiring an additional 239 shares during the last quarter. UMB Bank n.a. boosted its stake in shares of Enovis by 128.2% during the 4th quarter. UMB Bank n.a. now owns 778 shares of the company's stock worth $34,000 after acquiring an additional 437 shares during the last quarter. Pinnacle Bancorp Inc. boosted its stake in shares of Enovis by 54.5% during the 4th quarter. Pinnacle Bancorp Inc. now owns 850 shares of the company's stock worth $37,000 after acquiring an additional 300 shares during the last quarter. Finally, Quarry LP boosted its stake in shares of Enovis by 506.1% during the 4th quarter. Quarry LP now owns 897 shares of the company's stock worth $39,000 after acquiring an additional 749 shares during the last quarter. Institutional investors own 98.45% of the company's stock.

Enovis Price Performance

Shares of ENOV stock traded up $0.37 on Friday, hitting $36.10. 539,929 shares of the stock traded hands, compared to its average volume of 780,866. The company has a debt-to-equity ratio of 0.40, a current ratio of 2.27 and a quick ratio of 1.12. The firm has a market cap of $2.06 billion, a price-to-earnings ratio of -16.49 and a beta of 1.79. The firm has a 50 day simple moving average of $35.15 and a two-hundred day simple moving average of $41.42. Enovis Co. has a 52 week low of $29.32 and a 52 week high of $52.76.

Enovis (NYSE:ENOV - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported $0.81 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.74 by $0.07. The company had revenue of $558.83 million for the quarter, compared to the consensus estimate of $558.80 million. Enovis had a negative net margin of 5.95% and a positive return on equity of 4.39%. Enovis's revenue for the quarter was up 8.2% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.50 EPS. As a group, equities research analysts predict that Enovis Co. will post 2.79 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on ENOV. Needham & Company LLC decreased their price objective on shares of Enovis from $64.00 to $57.00 and set a "buy" rating on the stock in a research report on Friday, May 9th. JMP Securities decreased their price objective on shares of Enovis from $62.00 to $55.00 and set a "market outperform" rating on the stock in a research report on Friday, May 9th. Finally, Canaccord Genuity Group decreased their price objective on shares of Enovis from $75.00 to $70.00 and set a "buy" rating on the stock in a research report on Wednesday. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $58.00.

About Enovis

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.